Vorolanib is an Orally Active Inhibitor of VEGFR and PDGFR
Vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) are cell-surface tyrosine kinase receptors. They represent targets for anticancer therapy in solid tumors. For accurately validating the…